Navigation Links
Anpac Bio Surpasses 40,000 Case Study Milestone 'Liquid Biopsy Pioneer' Serving Individual, Medical, Insurance & Corporate Customers
Date:3/28/2017

SACRAMENTO, Calif., March 28, 2017 /PRNewswire/ -- Dr. Chris Yu, Chief Executive Officer of international life sciences corporation Anpac Bio-Medical Science Company, announced this week the company set a new, international record, processing and reporting over 40,000 cases worldwide of the company's proprietary, "Cancer Differentiation Analysis" (CDA) liquid biopsy tests.

Described as "game changing", in World Nobel Prize Laureate Summit publications, Anpac Bio's CDA medical devices and technology effectively reinvents early cancer screening and detection. By analyzing simple, in vitro, liquid or "Blood Biopsies", and applying Anpac Bio's proprietary, multi-level, multi-parameter, diagnostic algorithms, Anpac Bio's CDA technology identifies cancer with measurably-greater sensitivity, specificity, and accuracy, than most current, conventional screening methods. And it does so without any harmful side effects in patients; generating far fewer "false positives"; and at a cost substantially lower than traditional testing.

Continue Reading
International life sciences leader Anpac Bio-Medical Science Company has developed breakthrough, proprietary, "Cancer Differentiation Analysis" technology that effectively reinvents cancer screening and early detection. Anpac's proprietary CDA medical devices analyze simple, standard, non-invasive "Blood Biopsies" - resulting in measurably greater early cancer detection sensitivity and specificity, with no harmful side effects in patients. The proven results of 25,000 cases to date demonstrate CDA's research validity achieving an average sensitivity and specificity rate range of 75%-90% for ten different types of cancer -- often identifying the type and location of threatening, diseased cancer cells before they form into tumors. (PRNewsFoto/Anpac Bio-Medical Science Co.) (PRNewsFoto/Anpac Bio-Medical Science Co.)
International life sciences leader Anpac Bio-Medical Science Company has developed breakthrough, proprietary, "Cancer Differentiation Analysis" technology that effectively reinvents cancer screening and early detection. Anpac's proprietary CDA medical devices analyze simple, standard, non-invasive "Blood Biopsies" - resulting in measurably greater early cancer detection sensitivity and specificity, with no harmful side effects in patients. The proven results of 25,000 cases...

Comprehensive research validity data from the 40,000 cases processed to date indicate Anpac Bio's CDA diagnostics far exceed existing or competing technologies - revealing a sensitivity and specificity rate range of 75%-90% for over 16 different types of cancer – most at the disease's earliest stages.

"Since our company launched in 2008, we have really pioneered the 'liquid biopsy' space," states Dr. Yu. "Because our CDA devices have already been approved by international regulatory bodies, and our research has been published and presented before respected scientific organizations, like the American Society of Clinical Oncology (ASCO) and the World Nobel Prize Laureate Summit, our CDA tests are in really great demand right now. We've processed over 40,000 CDA tests for individuals; and organizations such as health systems, insurance companies, corporations, and educational institutions. We're very proud our CDA devices have advanced beyond the laboratory, and are processing real tests for real people. And we have dozens of testimonials from people saying our CDA tests detected their early-stage cancer and saved their lives. At this rate, we project to double our CDA cases worldwide and save many more lives, by 2018!"

Anpac Bio maintains research and development, and manufacturing operations, in six sites worldwide, employing over 100 people. Filing over 150 CDA technology-related patent applications internationally to date, the company presented its latest research results, "Investigations of a novel diagnostic technology for colorectal cancer", at the ASCO 2017 Gastrointestinal Cancers Symposium.

 For more information regarding Anpac Bio: www.AnpacBio.com.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/anpac-bio-surpasses-40000-case-study-milestone-liquid-biopsy-pioneer-serving-individual-medical-insurance--corporate-customers-300430286.html


'/>"/>
SOURCE Anpac Bio-Medical Science Company
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Anpac Bio-Medical Moves U.S. Headquarters to Sacramento
2. Anpac Bio-Medical Presents Cancer Differentiation Analysis Research at Nobel Laureate Cancer Research Summit
3. PROMPT Patient Registry, Based on PatientCrossroads Platform, Surpasses Enrollment Goals With More Than 1,600 Participants
4. Global biotech industry continues to sizzle as market capitalization surpasses US$1 trillion
5. ACGT Surpasses $25 Million Funding Milestone with Two New Grants
6. French Man Surpasses Two Years of Support with SynCardia Total Artificial Heart
7. SynCardia Total Artificial Heart Surpasses 100th Implant of 2013
8. YouTube Channel on SEO Tips Surpasses 175,000 Views, Announces JM Internet Group
9. 40,000 Patients Come Together with Researchers and Doctors to Create $40 Million Game-Changing IBD Research Initiative
10. Yale Study Published in JNCCN Uncovers Racial Disparities in Treatment of Women with Breast Cancer
11. Celltex autologous stem cell case study published in Stem Cells and Development demonstrates favorable response in pediatric patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/11/2019)... ... June 11, 2019 , ... Veterinary Regenerative Medicine company, ... , has announced that their GMP facility for cell production is now approved ... This is an important milestone for VetStem as it expands into contract ...
(Date:5/31/2019)... ... May 30, 2019 , ... World Compliance Seminars today announced ... 2019 in Boston, MA. This peer recommended interactive workshop is always selected by ... will kick off with a compendial treatment of Data Integrity fundamentals. After laying ...
(Date:5/15/2019)... ... ... Milton Hershey School® has named William Charles Ballough Harding ’78 the 2019 ... he is changing lives by creating solutions to global healthcare challenges through the development ... our founders – Milton and Catherine Hershey – who always hoped for Milton Hershey ...
(Date:5/7/2019)... Columbia (PRWEB) , ... May 06, 2019 , ... ... a go-to resource for the growing number of repositories being asked to store ... are grateful to the team of contributors who are world leaders, who have ...
Breaking Biology Technology:
(Date:6/11/2019)... ... June 12, 2019 , ... ... services, Abveris plans to leverage the Geneious Biologics platform as a premium hub ... Technology Officer at Abveris, says: “The Geneious team has done an excellent job ...
(Date:6/6/2019)... , ... June 05, 2019 , ... ... as the exclusive financial advisor to Pathologists Bio-Medical Laboratories (PBM) on its recent ... preeminent anatomic pathology platform that provides services to more than one dozen hospitals ...
(Date:6/4/2019)... ... June 04, 2019 , ... ... for salient features of seizure risk signals, usually based on variations of amplitude, ... remains the only acceptable diagnostic methodology due to the complexity and variability of ...
Breaking Biology News(10 mins):